Global HPV Testing and Pap Test Market

HPV Testing and Pap Test Market size was valued at USD 3.92 Billion in 2023 and the total HPV Testing and Pap Test Market is expected to grow at a CAGR of 6.1% from 2024 to 2030, reaching nearly USD 5.94 Billion.

Overview

The report discusses the scope for the testing of Human papillomavirus (HPV), a sexually transmissible infection that is the most common in the world, belonging to the papillomaviridae family. HPV is a double-stranded DNA tumour virus that causes epithelial proliferation at cutaneous and mucosal surfaces. HPV is categorized into two groups, low-risk and high-risk, depending on the associated risk. There are about 14 high-risk HPV types, which are established as the causative agents responsible for cervical and vaginal cancer. The most oncogenic type of HPV is HPV 16, accounting for almost half of all cervical cancers, while HPV 16 and 18 together account for approximately 70% of cervical cancers. Cervical cancer screening is a crucial part of a woman's routine health check-up as it can diagnose abnormalities that could result in cancer of the cervix. Pap tests, HPV testing, and co-tests are included in cervical cancer screening.

The HPV test checks cells for infection with high-risk HPV types that can cause cervical cancer. The Pap test collects cervical cells to check for changes caused by HPV that may, if left untreated, turn into cervical cancer. The HPV/Pap co-test uses an HPV test and Pap test together to check for both high-risk HPV and cervical cell changes. The pharmaceutical industry is experiencing growth and innovation in the manufacturing of screening test kits, creating an opportunity in the HPV testing and PAP test market. This is due to an increase in health-conscious consumers and the prevalence of cervical cancer cases. Key trends driving market growth include the launch of various screening test kits and new specific HPV type testing kits. However, changes in regulatory guidelines and the availability of HPV vaccination may hinder market growth.To know about the Research Methodology :- Request Free Sample Report

Competitive Landscapes:

The global HPV testing and PAP test market is highly competitive, with companies focusing on developing innovative test kits to meet the high demand for efficient and cost-effective testing. In May 2022, Alercell, Inc announced its HPV DNA-based test kit, Meltpro HPV genotype test, based on DNA sequencing analysis, which eliminates the risk of human interpretation and provides faster results. In June 2022, Roche launched a new HPV self-sampling solution in countries accepting the CE mark, allowing patients to privately collect samples for HPV screening. With high prevalence of cervical cancer in many regions, the industry is attracting new players, and both new entrants and established players are looking to expand their research through strategic collaborations and acquisitions. This intense competition is expected to continue driving innovation and advancements in the HPV testing and PAP test market.

HPV Testing And Pap Test Market Dynamics:

Growth driver for the market:

Increasing Prevalence of Cervical Cancer Driving Growth of HPV Testing and PAP Test Market

Cervical cancer is a major health concern worldwide, with over half a million new cases and 342,000 deaths reported in 2021. The high incidence of cervical cancer is primarily due to human papillomavirus (HPV), which is responsible for 90% of cervical cancer cases. To address this issue, WHO has endorsed a global strategy for cervical cancer elimination, which aims to screen 70% of women globally for cervical disease using high-performance tests and provide appropriate treatment to 90% of those who need it.

The increasing number of cervical cancer cases globally has led to a growing demand for screening programs. The HPV testing and PAP test market is expected to witness growth due to the rising demand for these tests. The market is highly competitive, with players such as Qiagen NV offering technologically advanced tests that detect HPV DNA, such as the Capture 2 test, which can detect the presence of 13 high-risk HPV types in the cervical sample.

In the United States, about 14,110 new cases of invasive cervical cancer were diagnosed in 2023. This further emphasizes the need for regular screening for cervical cancer, and the market is expected to grow as a result. The market growth is further driven by the increasing awareness among women regarding the importance of early detection and prevention of cervical cancer.

HPV Testing And Pap Test Market Opportunity:

Initiatives by the government are expected to drive the market during the forecast period

The HPV testing and PAP test market is witnessing growth due to various government initiatives and policies worldwide. In the USA, the CDC recommends regular screening for cervical cancer using either a Pap test or an HPV test, depending on the woman's age. The frequency of screening varies, with recommendations of every 3 years for women aged 21-29 and every 3-5 years for women over 30.

Similarly, in China, a dual program for screening cervical and breast cancer in rural women has been launched by the All-China Women's Federation and the Ministry of Health, with screening intervals of 3 years. In Japan, the National Cancer Center recommends screening every 2 years, with most cities offering free or subsidized options for eligible women. In South Korea, eligible women over 20 years of age are provided a free screening once every 2 years, thanks to the country's single-payer public health insurance system.

The rising number of awareness programs by various organizations to drive the market

Furthermore, the rising number of awareness programs by various organizations, including the National Cervical Cancer Coalition, WHO, CDC, and the U.S. Preventive Services Task Force, is also driving the market for HPV testing and Pap test. For instance, in March 2019, the UK government launched its first national cervical screening campaign called Cervical Screening Saves Lives, aimed at increasing awareness about the disease and encouraging more women to undergo screening.

All these initiatives and policies are expected to drive the growth of the HPV testing and PAP test market during the forecast period. The market is highly competitive, with industry rivalry among companies offering technologically advanced tests. Regular screening and early detection of cervical cancer are crucial for the prevention and management of this disease, and the market is expected to continue to grow in the future.

HPV Testing and Pap Test Market Segment Analysis:

Based on Test Type

By test type the market is segmented into HPV Testing and Pap Test. The Pap test dominates the HPV testing and Pap test market with more than 50% revenue share due to its widespread use in screening programs. The segment's growth is expected to be fuelled by initiatives to increase awareness about Pap tests. Meanwhile, the HPV testing segment is anticipated to the highest growth over the forecast period, mainly due to the commercialization of innovative tests and increasing government recommendations to use more efficient HPV screenings.

DNA-based HPV tests can detect specific strains of the virus in the specimen and help detect abnormal cells that may become cancerous. Early detection can lead to early prevention, allowing healthcare professionals to opt for various treatment and/or preventive options. Several organizations and campaigns, such as Public Health England's Cervical Screening Saves Lives and New Zealand Health's "Smear your Mea," are working towards increasing awareness and encouraging women to undergo regular screening.

Based on Application

The market for HPV testing and PAP tests is dominated by the cervical cancer screening segment. The dominance and fast growth of this segment can be attributed to the higher incidence of cervical cancer as compared to vaginal cancer. Moreover, continuous public-private initiatives to increase cervical cancer screening rates are also expected to support the growth of this segment. The World Health Organization's (WHO) Plan of Action for Cervical Cancer Prevention and Control 2018-2030 is one such initiative aimed at improving screening and timely treatment of cervical cancer through innovative strategies.

The vaginal cancer screening segment is also expected to witness a significant CAGR during the forecast period. The increasing prevalence and high mortality rates of vaginal cancer have propelled the demand for effective screening tests, vaginal cancer affects 1 out of every 1,100 women. In 2022, 6000 women were diagnosed with vaginal cancer in the U.S. The number of vaginal cancer-related deaths in the U.S. was 1,430 in the same year

Based on Product

By the product, the market is categorised into Instruments, Consumables and Services the HPV testing and PAP test market is dominated by the consumables segment in 2023 due to its repetitive usage in HPV and cervical screenings. The segment is expected to continue growing due to continuous development activities and the introduction of innovative consumables, such as assays & kits, which enhance the accuracy of HPV and PAP diagnoses. For example, Becton, Dickinson and Company's submission of a Premarket Approval application to the FDA for the usage of Thin Prep Pap Test PreservCyt Solution vial with its on clarity HPV Assay aims to expand the usage of the On clarity HPV Assay in the U.S. and improve patient management.

The services segment is expected to witness the fastest CAGR during the forecast period, driven by the introduction of self and at-home HPV screening services, which increase the frequency of cervical cancer screening rates in key markets. Nurx, a U.S.-based telemedicine company, introduced its Home HPV Screening test in January 2019, enabling women to identify their risk affordably and conveniently for cervical cancer from home in the U.S

Based on Technology

The HPV testing and PAP test market is comprised of various segments including PCR Immunodiagnostics and Other Technologies. In 2023, the other technologies segment dominated the market, accounting for almost half of the revenue share. This segment's success can be attributed to the widespread use of colposcopy and cystoscopy techniques in HPV and cervical cancer screenings. These examinations allow doctors to examine a woman's cervix, vagina, and vulva for signs of disease.

However, the PCR segment is expected to experience significant growth due to new guidelines for utilizing DNA HPV testing methods, which are more accurate and cost-effective. PCR for HPV testing is especially useful in identifying risky lesions in women aged 30 and above with normal cytology results, improving the sensitivity of cervical cancer screening programs. It also reduces the need for unnecessary colposcopy and treatment in women aged 21 and above with cytology results indicating atypical squamous cells of undetermined significance.

Based on End User

By the End user the market segmented into hospitals & clinics, Laboratories & others. The market for HPV testing and Pap tests is dominated by the hospitals and clinics segment, which accounted for the largest revenue share in 2023. Hospitals and clinics serve as primary care settings for the diagnosis and treatment of diseases, including HPV infections and cervical cancer. The rise in healthcare expenditure globally and continuous changes in the healthcare industry have led to an increase in the need for hospitals and clinics with enhanced diagnostic services

Home care settings segment is expected to witness the fastest growth in the forecast period as a result of the increasing use of POC (point-of-care) tests. Recent advancements in POC test kits have resulted in shorter turnaround times and error-free results, which is expected to boost the market for HPV testing and Pap tests over the forecast years. However, the lack of availability of highly accurate POC testing kits is expected to be a significant factor hampering its market growth during the study period. The growing adoption of self-sampling for cervical cancer screening is also anticipated to significantly support the growth of the industry. Self-sampling of HPV has the potential to overcome various identified barriers, such as cultural and community

HPV Testing and Pap Test Market Regional Insights:

By Region the market is segmented into North America, South America, Asia Pacific, Europe & Milled East Africa. North America is the dominant region in the HPV testing and Pap test market in 2023 and is expected to continue leading in the forecast period. The growth of the market in the region can be attributed to high awareness about the importance of early diagnosis of cervical cancer, established screening guidelines, and favourable healthcare reimbursement policies. Additionally, the affordability, adoption, and access to technologically advanced products and services have further boosted the market's growth in the region. The presence of leading players with headquarters in the U.S. and ongoing strategic initiatives taken by them have also supported the growth of the market in North America.

In the Asia Pacific region, the HPV testing and Pap test market is projected to exhibit an exponential CAGR during the forecast period. This high growth is attributed to the high prevalence of HPV and cervical cancer in key countries, such as Japan, China, and India.

Technological advancements in the region are also anticipated to fuel the market's growth. Public-private initiatives aimed at improving cervical cancer screening in the region are also expected to contribute significantly to the market's growth during the forecast period. Overall, the HPV testing and Pap test market is showing promising growth prospects, with significant opportunities for market players to expand and innovate their offerings.

HPV Testing and Pap Test Market Scope: Inquiry Before Buying

HPV Testing and Pap Test Market, by Region

North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina Rest of South America)

HPV Testing and Pap Test Key Players:

1. Abbott Laboratories
2.  Qiagen N.V.
3.  Becton, Dickinson and Company
4.  Quest Diagnostics, Inc.
5.  Hologic, Inc.
6.  F. Hoffmann-La Roche
7.  Femasys, Inc.
8. Arbor Vita Corporation
9.  NURX, Inc.
10. Seegene, Inc.
11. Thermo Fisher Scientific, Inc.
12. bioMérieux SA
13. Takara Bio Inc
14.  Promega Corporation
15.  Fujirebio Diagnostics, Inc
16. TruScreen.
17.  Onco Health Corporation

FAQs:

1] What segments are covered in the Global HPV Testing and Pap Test Market report?
Ans. The segments covered in the HPV Testing and Pap Test report are based on test type, application, product, test type, end user and region.

2] Which region is expected to hold the highest share in the Global HPV Testing and Pap Test Market during the forecast period?
Ans. The North America region is expected to hold the highest share of the HPV Testing and Pap Test market during the forecast period.

3] What is the market size of the Global HPV Testing and Pap Test by 2030?
Ans. The market size of the HPV Testing and Pap Test by 2030 is expected to reach US$ 5.94 Bn.

4] What is the forecast period for the Global HPV Testing and Pap Test Market?
Ans. The forecast period for the HPV Testing and Pap Test market is 2024-2030.

5] What was the market size of the Global HPV Testing and Pap Test in 2023?
Ans. The market size of the HPV Testing and Pap Test in 2023 was valued at US$ 3.92 Bn.